ADAMTS-5 Decreases in Coronary Arteries and Plasma from Patients with Coronary Artery Disease

Figures

• 

  Figure 1. The ADAMTS-5 expression in human atheromatous plaques. (a) Western blot analysis of ADAMTS-5 in atheromatous plaques from normal donors and patients with coronary heart disease (CAD) (n = 6/group). ∗P < 0.05 versus donors. (b) The ADAMTS-5 expression in these two groups were measured by immunohistochemistry staining (n = 6/group, scale bar, 1000 μm for the left set of panels and 100 μm for the right panels). (c) The source of ADAMTS-5 was detected by double immunofluorescence staining (n = 6/group, scale bar, 100 μm).

• 

  Figure 2. Plasma cytokine levels in each group. The plasma levels of ADAMTS-5 (a), MMP-2 (b), and MMP-9 (c) in NCAD (n = 36) and CAD (n = 123) groups were measured by ELISA. Spearman's correlation between the plasma levels of MMP-2 (d), MMP-9 (e), and ADAMTS-5 in CAD patients (n = 123). (f) Correlation between MMP-2 levels and MMP-9 levels (n = 123).

• 

  Figure 3. Correlation between plasma cytokine levels and Gensini score. Spearman's correlations between the plasma ADAMTS-5 (a), MMP-2 (b), and MMP-9 levels (c) and the Gensini score in the patients with CAD (n = 123).

• 

  Figure 4. Correlation analysis of ADAMTS-5 (a), MMP-2 (b), and MMP-9 levels (c) and the Gensini score (d) with circulating CRP levels in the patients with CAD (n = 123).

• 

  Figure 5. The ROC curve of ADAMTS-5, MMP-2, MMP-9, and combining the three cytokines for the diagnostic value of CAD.